ReviewDiscover oncology2025
Crossroads of cell fate: miR-34-mediated regulation of apoptosis and autophagy in glioblastoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive and treatment-resistant form of primary brain tumor, characterized by rapid proliferation, extensive heterogeneity, and evasion of programmed cell death. Among emerging molecular regulators, microRNA-34 (miR-34) has gained attention as a potent tumor suppressor with the ability to modulate key signaling pathways involved in cell survival and death. This review explores the dual role of miR-34 in orchestrating apoptosis and autophagy, two fundamental processes that determine glioblastoma cell fate. We summarize current findings on how miR-34 directly targets genes involved in apoptotic signaling-such as BCL2, SIRT1, and NOTCH1-thereby promoting cell death and sensitizing GBM cells to therapeutic agents. Additionally, we highlight the context-dependent influence of miR-34 on autophagic flux, where it can either facilitate cytoprotective responses or trigger autophagy-associated cell death. Understanding this regulatory balance provides insight into the cellular plasticity of GBM and opens new avenues for therapeutic intervention. Targeting miR-34 or its downstream pathways offers promising potential to overcome resistance mechanisms and improve outcomes in glioblastoma treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.